Evolus Reports 3.7% Revenue Growth to $69.4 Million in Q2 2025

Evolus, Inc. reported its financial results for the second quarter of 2025, revealing a net revenue of $69.4 million, a 3.7% increase from $66.9 million in the same period last year. The growth was primarily driven by the recent launch of the Evolysse™ product line, which contributed $9.7 million in revenue. However, the company experienced a decline in sales of its flagship product, Jeuveau®, attributed to a decrease in patient demand influenced by broader macroeconomic factors. The gross profit margin for the quarter was 65.3%, down from 70.3% in the prior year, reflecting increased costs associated with the new product mix.

In terms of profitability, Evolus reported a net loss of $17.1 million for the quarter, compared to a loss of $11.4 million in the same quarter of 2024. The increase in losses was driven by higher operating expenses, which rose to $55.5 million from $54.8 million year-over-year. Notably, selling, general, and administrative expenses increased by 13% to $56.7 million, largely due to costs associated with the Evolysse™ launch. Research and development expenses decreased slightly, reflecting a shift in focus towards commercialization efforts.

Evolus has made significant strategic moves, including the launch of Evolysse™ Form and Evolysse™ Smooth in April 2025, with plans to introduce additional products in Europe by early 2026. The company also entered into an Amended and Restated Loan Agreement with Pharmakon, securing a senior secured term loan of up to $250 million, which will support ongoing operations and product development. As of June 30, 2025, Evolus had cash and cash equivalents of $61.7 million, down from $86.9 million at the end of 2024, and an accumulated deficit of $645.4 million.

Operationally, Evolus is focused on expanding its customer base and increasing product adoption in a competitive market. The company reported a slight increase in accounts receivable and inventory levels, indicating a strategic buildup in anticipation of future sales. The total employee headcount has also increased as the company ramps up its marketing and sales efforts. Evolus continues to face challenges related to market conditions, including inflation and consumer spending trends, which may impact future performance.

Looking ahead, Evolus remains optimistic about its growth trajectory, particularly with the anticipated regulatory approvals for additional Evolysse™ products. The company expects that its ability to navigate the competitive landscape and effectively market its products will be crucial for achieving sustained revenue growth. However, management cautioned that ongoing economic uncertainties could pose risks to achieving these objectives.